Drug Trial Radar · NCT05417321
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Aug 25, 2022
Primary completion
Aug 1, 2025
Study completion Aug 1, 2025
Sponsor
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors
Conditions
- Advanced Solid Tumor
- NSCLC
Interventions
HB0036Drug
Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: Up to 12 Months
- MTDTime frame: Up to 24 Months
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Horizon Oncology
Lafayette, Indiana · Recruiting
Next Oncology
San Antonio, Texas · Recruiting
Summit Cancer Centers
Spokane, Washington · Recruiting
Shandong Hospital
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.